We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
Allogene Therapeutics
Biotechnology
South San Francisco, California 64,284 followers
About us
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
-
www.allogene.com
External link for Allogene Therapeutics
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Locations
-
Primary
210 E Grand Ave
South San Francisco, California 94080, US
-
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Updates
-
We are pleased to announce activation of three community cancer centers as first sites open in our pivotal Phase 2 ALPHA3 trial evaluating cema-cel as part of 1L treatment in #LBCL. Patient screening underway at Rocky Mountain Cancer Centers (RMCC), part of the Sarah Cannon Research Institute and US Oncology Network (Colorado), Astera Cancer Care (ACC), part of the OneOncology Network (New Jersey), and Norton Healthcare. #CART #celltherapy Foresight Diagnostics. https://lnkd.in/gRCrNcE9
-
Our own Zach Roberts provides his perspective on how allogeneic CAR T products may be a solution to problems facing autologous CAR T products for patients with #CLL in the latest issue of Cell & Gene. #Immunotherapy #CART
The Path Forward for CLL is Allogeneic https://lnkd.in/euvZhyWK By Zachary J Roberts MD PhD, Executive Vice President, Research & Development, and Chief Medical Officer, Allogene Therapeutics Chronic lymphocytic leukemia (CLL) remains a disease that is managed, not one that is often cured.
-
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene: Allogene.com/Science
-
-
Thrilled to announce the initiation of our groundbreaking 1L consolidation ALPHA3 trial, which has the potential to redefine the future of CAR T and treatment of LBCL, and expand access in the community cancer setting. Foresight Diagnostics $ALLO #CART #celltherapy #immunotherapy Learn more about ALPHA3: https://lnkd.in/g_sxiYVw
-
Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home
-
Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329: Allogene.com/Pipeline
-
Looking forward to hearing Zachary J Roberts MD PhD talk about the potential of CAR T in earlier lines of cancer treatment at the 6th Allogeneic Cell Therapies Summit on June 12. $ALLO #CART #celltherapy #immunotherapy Hanson Wade Group Learn more here: https://lnkd.in/gUxJCtSv
-
-
Tim Moore, Chief Technical Officer of Allogene, is featured in this month’s issue of BioProcess International with his take on the potential of off-the-shelf allogeneic #CAR T products to revolutionize cancer care. #celltherapy #immunotherapy https://lnkd.in/ggAz2PPa
Allogeneic Cell Therapy
bioprocessintl.com